S-1/A: Kairos Pharma Seeks $6.2 Million in IPO to Advance Cancer Therapeutics

Kairos Pharma aims to raise capital through an initial public offering to fund clinical trials and further develop its pipeline of cancer therapeutics.

Summary

• Kairos Pharma, a clinical-stage biopharmaceutical company, is seeking to raise $6.2 million through an initial public offering of 1,550,000 shares of common stock at an expected price of $4.00 per share.
• The company intends to use the net proceeds to fund Phase 1 and Phase 2 clinical trials for its product candidates, including ENV 105 and KROS 101, as well as for potential acquisitions, in-licensing activities, working capital, and general corporate purposes.
• Kairos Pharma's pipeline includes seven drug candidates targeting various cancers, such as prostate cancer, lung cancer, breast cancer, and glioblastoma.
• The company's lead product candidate, ENV 105, is currently in Phase 2 clinical trials for prostate cancer and Phase 1 trials for lung cancer.
• The closing of the offering is contingent upon the approval of Kairos Pharma's listing application on the NYSE American LLC under the symbol KAPA.
• Boustead Securities, LLC and EF Hutton LLC are acting as underwriters for the offering.
• The company has a limited operating history and has incurred significant losses since its inception, expecting to continue incurring losses for the foreseeable future.
• Kairos Pharma relies on licensing agreements with Cedars-Sinai Medical Center and Tracon Pharmaceuticals, Inc. for its intellectual property.
• The company is an emerging growth company and a smaller reporting company, which allows it to take advantage of certain exemptions from public company reporting requirements.

Sentiment

Score: 5

Explanation: The document presents a balanced view, highlighting both the potential of Kairos Pharma's cancer therapeutics and the risks associated with investing in a clinical-stage biopharmaceutical company. The sentiment is neutral, reflecting the inherent uncertainties in the drug development process.

Positives

• The company has a diversified portfolio of seven drug candidates, mitigating the risk associated with drug development.
• ENV 105 has shown promising results in a Phase 2 trial, with a 62% clinical benefit rate observed in prostate cancer patients resistant to androgen-targeted therapy.
• The company has established partnerships with reputable institutions like Cedars-Sinai Medical Center and Tracon Pharmaceuticals, Inc.
• The company is leveraging a virtual infrastructure for efficient execution of collaborative clinical and translational research.
• The company has filed an IND with the FDA for ENV 105, and has begun enrolling patients in Phase 1 and Phase 2 trials.

Negatives

• The company has a limited operating history and has incurred significant losses since its inception.
• The company will need to obtain substantial additional funding to meet its financial needs and pursue its business objectives.
• The company is relying exclusively on the skills and expertise of its management team, not all of whom will devote all of their time to managing the company.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company's exclusive licensing rights to its intellectual property are subject to agreements with third parties and it may not meet milestones set forth in those agreements or its exclusive licensing rights may be terminated.

Risks

• The company requires substantial additional funding to meet its financial needs and to pursue its business objectives.
• The company's limited operating history may make it difficult for investors to evaluate the success of its business to date and to assess its future viability.
• The company faces substantial competition, which may result in others discovering, developing, or commercializing products before or more successfully than it does.
• The company is relying exclusively on the skills and expertise of its management team, not all of whom will devote all of their time to managing the company, and it currently has no full-time employees, which may impede its ability to carry on its business.
• The company operates with a small team and its future success depends on its ability to retain key executives and to attract, retain, and motivate qualified personnel.
• The company's exclusive licensing rights to its intellectual property are subject to agreements with third parties and it may not meet milestones set forth in those agreements or its exclusive licensing rights may be terminated.
• If the company is unable to obtain and maintain patent and other intellectual property protection for its technology, or for any its current in-development products or its future product candidates, or if the scope of the patent and other intellectual property protection obtained is not sufficiently broad, its competitors could develop and commercialize technology and drugs similar or identical to ours, and its ability to successfully commercialize its technology and product candidates may be impaired.
• As an organization, the company has limited experience designing and implementing clinical trials and it has never conducted pivotal clinical trials.
• If the company is not able to obtain, or if there are delays in obtaining, required regulatory approvals, it will not be able to commercialize its current in-development products or its future product candidates, and its ability to generate revenue will be materially impaired.
• If the company is unable to successfully develop any required companion diagnostic tests for its product candidates, experience significant delays in doing so, or rely on third parties in the development of such companion diagnostic tests, it may not realize the full commercial potential of its product candidates.
• Preclinical development is uncertain.
• The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable.
• The company has identified material weaknesses in its internal control over financial reporting.
• The closing of this offering is contingent on the company obtaining listing on the NYSE American.
• If investors purchase common stock in this offering, they will suffer immediate dilution of their investment.
• The trading price of the company's common stock may be volatile, and investors could lose all or part of their investment.

Future Outlook

The company expects to continue incurring significant and increasing expenses and operating losses for the foreseeable future as it advances its product candidates through clinical development, seeks regulatory approval, and operates as a public company.

Management Comments

• Our goal is to unlock the power of the immune system on the two most pervasive problems in cancer treatment: resistance to therapy and immune suppression by cancer.
• We believe this road will lead to major improvement in the quality of life of cancer patients and will transform patient outcomes.

Industry Context

The document highlights the competitive landscape of the biopharmaceutical industry, particularly in immuno-oncology, where Kairos Pharma faces competition from major pharmaceutical companies, academic institutions, and research organizations. The company's success depends on its ability to develop and commercialize products that are safer, more effective, and less expensive than existing therapies.

Comparison to Industry Standards

• The document mentions that the global prostate cancer therapeutics market was valued at USD 7.9 billion and at USD 1.7 billion for EGFR mutant non-small cell lung cancer.
• The document mentions that androgen targeted therapy accounts for USD 15 billion in sales in 8 primary markets.
• The document mentions that the global head & neck cancer drug market is estimated at $1.51 billion in 2021.
• The document mentions that the global small-molecule cancer therapies market size was valued at $175.3 billion in 2021 and is expected to have a CAGR of 5.44% from 2022 to 2030.
• The document mentions that the global peptide therapeutics market size was estimated at $39.3 billion in 2021 and is expected to reach $42.1 billion in 2022.
• The document mentions that the T cell therapy market size is expected to be around $20.8 billion by 2030 from its value of $4.9 billion in 2021 with a CAGR of 20.4% during the forecast period 2022-2030.
• The document mentions that the global immune checkpoint inhibitor market size was $31.4 billion in 2021 and anticipated to be $148 billion in 2020 with a CAGR of 18.81% from 2022 to 2030.

Related Party Transactions

• During the year ended December 31, 2021, shareholders of the Company, and a company whose principal stockholder is also a stockholder of the Company, advanced the Company $0.01 million, all of which was outstanding at December 31, 2021.
• During the year ended December 31, 2022, the Company repaid $0.01 million of the advances, and as of December 31, 2022 and 2023, a total of $0.004 million remained outstanding.
• Subsequent to December 31, 2023, two officers and shareholders agreed to convert the $0.004 million due to them into 1,664 shares of the Companys common stock, effective upon the closing of the Companys IPO.
• Subsequent to December 31, 2023, the Company borrowed $0.07 million from three of its officers.

Stakeholder Impact

• Shareholders will experience dilution as a result of the IPO and potential future financings.
• Employees may benefit from the company's growth and success, but also face risks associated with the company's financial condition and the competitive landscape.
• Patients may benefit from the development of new and effective cancer therapies.
• The company's suppliers and collaborators may be impacted by its financial performance and ability to meet its obligations.

Next Steps

• Complete Phase 1 and Phase 2 clinical trials of ENV 105.
• Complete pre-IND studies for KROS 101.
• Initiate a Phase 1 trial of activated T cell therapy for KROS 201 in patients with glioblastoma.
• Continue to advance the pipeline of immunotherapeutics for clinical trials.
• Seek regulatory approval for product candidates.

Key Dates

Keywords

Kairos Pharma, IPO, cancer therapeutics, ENV 105, KROS 101, clinical trials, biopharmaceutical, drug resistance, immune suppression, oncology